LoginSignup
Argenx logo

Argenx Stock

StockStock
ISIN: NL0010832176
Ticker: ARGX
NL0010832176
ARGX

Price

Frequently asked questions

What is Argenx's market capitalization?

The market capitalization of Argenx is $35.72B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Argenx?

Argenx's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$0.837. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Argenx's stock?

Currently, 20 analysts cover Argenx's stock, with a consensus target price of $480.63. Analyst ratings provide insights into the stock's expected performance.

What is Argenx's revenue over the trailing twelve months?

Over the trailing twelve months, Argenx reported a revenue of $1.85B.

What is the EBITDA for Argenx?

Argenx's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$255.45M. EBITDA measures the company's overall financial performance.

What is the 5-year beta of Argenx's stock?

The 5-year beta for Argenx is 0.56. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Argenx have, and what sector and industry does it belong to?

Argenx employs approximately 1,148 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Argenx's shares?

The free float of Argenx is 59.72M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $35.72B

5Y beta

 0.56

EPS (TTM)

 -$0.837

Free Float

 59.72M

Revenue (TTM)

 $1.85B

EBITDA (TTM)

 -$255.45M

Pricing

1D span
$583.29$601.09
52W span
$297.58$616.83

Analyst Ratings

The price target is $480.63 and the stock is covered by 20 analysts.

Buy

14

Hold

5

Sell

1

Information

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

1,148

Biotechnology & Drugs

Health Care

Identifier

ISIN

NL0010832176

Primary Ticker

ARGX

Knockouts

Join the conversation
Sign upLogin